New! View global litigation for patent families

WO2008098212A3 - Extended release formulations of glucagon and other peptides and proteins - Google Patents

Extended release formulations of glucagon and other peptides and proteins

Info

Publication number
WO2008098212A3
WO2008098212A3 PCT/US2008/053488 US2008053488W WO2008098212A3 WO 2008098212 A3 WO2008098212 A3 WO 2008098212A3 US 2008053488 W US2008053488 W US 2008053488W WO 2008098212 A3 WO2008098212 A3 WO 2008098212A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
glucagon
release
preparation
pharmaceutical
circulation
Prior art date
Application number
PCT/US2008/053488
Other languages
French (fr)
Other versions
WO2008098212A2 (en )
Inventor
Timothy Andrew Stewart
Solomon Tse
Gregory A Sacha
Michael J Akers
Original Assignee
Diobex Inc
Timothy Andrew Stewart
Solomon Tse
Gregory A Sacha
Michael J Akers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

A pharmaceutical preparation comprising a suspension of glucagon in the presence of a metallic cation and optionally an excipient provides for a sustained release of glucagon into the circulation of a treated patient following injection of pharmaceutical preparation.
PCT/US2008/053488 2007-02-08 2008-02-08 Extended release formulations of glucagon and other peptides and proteins WO2008098212A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US90050907 true 2007-02-08 2007-02-08
US60/900,509 2007-02-08

Publications (2)

Publication Number Publication Date
WO2008098212A2 true WO2008098212A2 (en) 2008-08-14
WO2008098212A3 true true WO2008098212A3 (en) 2008-10-16

Family

ID=39682449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053488 WO2008098212A3 (en) 2007-02-08 2008-02-08 Extended release formulations of glucagon and other peptides and proteins

Country Status (1)

Country Link
WO (1) WO2008098212A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6117811B2 (en) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド Formulations for the treatment of diabetes
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CN104902919A (en) 2012-12-21 2015-09-09 赛诺菲 Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3129395A1 (en) 2014-04-07 2017-02-15 Sanofi Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists
WO2015155141A1 (en) 2014-04-07 2015-10-15 Sanofi Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4
WO2015155140A1 (en) 2014-04-07 2015-10-15 Sanofi Dual glp-1 / glucagon receptor agonists derived from exendin-4
WO2016201248A1 (en) * 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US20060014670A1 (en) * 2002-12-27 2006-01-19 Green Daniel T Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US20060014670A1 (en) * 2002-12-27 2006-01-19 Green Daniel T Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists

Also Published As

Publication number Publication date Type
WO2008098212A2 (en) 2008-08-14 application

Similar Documents

Publication Publication Date Title
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008133208A1 (en) Method for enhancing immune response with peptide
WO2007124461A8 (en) Glp-1 compounds
WO2008050907A1 (en) Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
WO2006006729A1 (en) Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients
WO2008105507A1 (en) Therapeutic agent for spinal cord injury
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2009030066A1 (en) Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2007031030A1 (en) Drug for treating tumor and use thereof in the manufature of medicaments for treating tumor
WO2006051103A3 (en) Stable formulations of peptides
WO2009030065A1 (en) INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
WO2007080721A1 (en) Therapeutic agent for lewy body disease and prophylactic agent for lewy body disease
WO2006094737A8 (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2009109132A1 (en) A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases
Nikitin Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions
PLOS ONE Staff Correction: Vaccination of Mice Using the West Nile Virus E-Protein in a DNA Prime-Protein Boost Strategy Stimulates Cell-Mediated Immunity and Protects Mice against a Lethal Challenge
WO2006026915A1 (en) Pharmaceutical composition and method of treating hepatitis with arginases
WO2012158965A3 (en) Improved peptide pharmaceuticals for insulin resistance
WO2006108405B1 (en) Nanoparticle/active ingredient conjugate
WO2008046285A1 (en) The uses of the carboxy-amido-triazole compounds and salts thereof
WO2013119061A1 (en) Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same
WO2009127140A1 (en) 7p peptide and its derivant, the use thereof
WO2008148247A1 (en) Cyclic analog of thymus pentapeptide, its preparing method and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08729452

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08729452

Country of ref document: EP

Kind code of ref document: A2